Send to

Choose Destination
Indian J Endocrinol Metab. 2015 Jan-Feb;19(1):129-35. doi: 10.4103/2230-8210.146868.

Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study.

Author information

Consultant Physician, DiaCare Clinic, Ahmedabad, Gujarat, India.
Consultant Endocrinologist, G. C. Reddy Clinic, Hyderabad, Andhra Pradesh, India.
Consultant Physician, Heart and Diabetes Care Hospital, Delhi, India.
Consultant Physician, Ashok Kumar, Kedia Clinic, Gorakhpur, Uttar Pradesh, India.
Medical Affairs, Bayer Zydus Pharma, Mumbai, Maharashtra, India.


Primary objective - evaluate effectiveness and safety of acarbose/metformin fixed dose FDC on glycemic control in Indian T2DM patients in real life clinical setting. Secondary objective - evaluate safety and satisfaction of treatment.


Open-label, prospective, multicentre, single-arm, non-interventional study. Patients included were aged ≥18 years with T2DM on Acarbose (25/50 mg) and Metformin (500 mg) FDC. Glycemic parameters were recorded during observation.


Total 9364 patients were enrolled in the study (mean age, 50.7 years and 60.1% were male). Mean (SD) FBG and PPG was significantly reduced by 42.4 (32.6) mg/dl (P < 0.0001) and 80.2 (49.7) mg/dl (P < 0.0001) respectively at the end of observation. Mean (SD) HbA1c reduced by -1.0% (0.8) to 7.3% (0.7) at the last follow-up visit (P <0.0001). Majority of patients (97.5%) and physicians (98.42%) were satisfied with acarbose/metformin FDC treatment. Also, significant reduction in body weight by -1.7 (2.2) kg was observed (P < 0.0001). Patients with known T2DM and newly diagnosed showed a similar glycemic control (P < 0.0001). Drug-related adverse events were reported by only 1.4% patients mostly gastrointestinal.


Acarbose/metformin FDC was efficacious, safe well accepted in routine clinical practice. It was well-tolerated without significant risk of hypoglycemia and can be used in early T2DM management.


Acarbose; HbA1c; India; Type 2 diabetes mellitus; alpha glucosidase inhibitor; combination; metformin; postprandial glucose

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center